Vaccine Response with Chemical Exposure
What You Need to Know Before You Apply
What is the purpose of this trial?
This clinical trial aims to investigate how exposure to Perfluorononanoic acid (PFNA), a type of per- and polyfluoroalkyl substance (PFAS), affects the immune response to the standard tetanus and diphtheria (Td) vaccine. The study focuses on participants from a community with known prior PFNA exposure through contaminated drinking water. The main question it aims to answer is:* Does exposure to PFNA weaken the body's initial immune response, leading to lower levels of protective antibodies after vaccination?Participants will:* Receive Tetanus and Diphtheria (Td) booster vaccination* Visit the study office 7 times over a 30-day period* Have blood and saliva collected at each study visit
Will I have to stop taking my current medications?
If you are currently taking immune suppressants, you will need to stop taking them to participate in this trial.
Is the vaccine generally safe for humans?
How does the drug TENIVAC differ from other treatments for chemical exposure?
TENIVAC is a vaccine typically used to prevent tetanus and diphtheria, and its use in the context of chemical exposure is unique because it is not a standard treatment for this condition. The trial may explore how the vaccine's immune response is affected by chemical exposure, which is not a common focus for other treatments.678910
Who Is on the Research Team?
Robert Laumbach, MD
Principal Investigator
Rutgers, The State University of New Jersey
Are You a Good Fit for This Trial?
This trial is for adults who have been exposed to PFNA through contaminated drinking water. It's designed to see if this exposure affects how their immune system responds to the Td vaccine. Participants will need to visit the study office seven times over a month and provide blood and saliva samples.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive Tetanus and Diphtheria (Td) booster vaccination and have blood and saliva collected at each visit
Follow-up
Participants are monitored for changes in Tetanus-diphtheria specific IgG levels
What Are the Treatments Tested in This Trial?
Interventions
- TENIVAC
Find a Clinic Near You
Who Is Running the Clinical Trial?
Rutgers, The State University of New Jersey
Lead Sponsor